TITLE

Trandolapril did not reduce cardiovascular death or other events in stable coronary artery disease: COMMENTARY

AUTHOR(S)
Granger, Christopher B.
PUB. DATE
May 2005
SOURCE
ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p66
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article reports that the PEACE trial, the latest in a trifecta of trials evaluating ACE inhibitors for patients who have cardiovascular disease without heart failure, did not show a benefit of trandolopril in patients with coronary aretery disease at low risk for complications. These results were surprising in light of the other trials, and the qualitatively different findings provide important information to clinicians. Possible explanations for the difference include the drug (including dose and compliance), the patient population, and chance. The authors carefully considered these possibilities and showed that compliance was only slightly lower than in other trials and that the drug and its dose had a clear biological effect in PEACE.
ACCESSION #
17116528

 

Related Articles

  • ACE inhibitors in heart failure: an update. Smith, W. H. T.; Ball, S. G. // Basic Research in Cardiology;Nov2000 Supplement 1, Vol. 95, pI8 

    Angiotensin-converting enzyme (ACE) inhibitors are now accepted as part of the routine management of patients with heart failure. Their use has been mandated in all the new major mortality trials to test the efficacy of β-blockers in heart failure. Morbidity and mortality remain high in those...

  • STICH: CABG plus ventricular reconstruction did not improve overall survival.  // Cardiology Today;May2010, Vol. 13 Issue 5, p12 

    The article discusses findings from an analysis of a Surgical Treatment for Intracerebral Hemorrhage (STICH) trial on the effect of incorporating Coronary Artery Bypass Graft (CABG) with surgical ventricular reconstruction (SVR) on the overall survival of patients with cardiovascular diseases.

  • In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events. Dans, Antonio L.; Koon Teo; Gao, Peggy; Jyh-Hong Chen; Kim Jae-Hyung; Yusoff, Khalid; Chaitraphan, Suphachai; Zhu, Jun; Liu Lisheng; Yusuf, Salim // PLoS Clinical Trials;Dec2010, Vol. 7 Issue 12, Special section p1 

    Background and Objectives: Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/ day) in reducing cardiovascular events. Clinicians in Asia...

  • The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. Tu, Karen; Mamdani, Muhammad M.; Jacka, Robert M.; Forde, Natalie J.; Rothwell, Deanna M.; Tu, Jack V. // CMAJ: Canadian Medical Association Journal;3/4/2003, Vol. 168 Issue 5, p553 

    Background: The Heart Outcomes Prevention Evaluation (HOPE), a Canadian-led, multicentre, randomized controlled trial, demonstrated the effectiveness of the ACE inhibitor ramipril in the secondary prevention of cardiovascular disease in patients who were at high risk for cardiovascular events...

  • Metastatic Malignant Melanoma Presenting as Congestive Heart Failure: Diagnosis by Transoesophageal Echocardiography. Schneider, B; Zienkiewicz, T // European Journal of Echocardiography;2002, Vol. 3 Issue 2, p168 

    The article presents a case study of a 58-year-old man with congestive heart failure, which requires mechanical ventilation. He has a history of arterial hypertension that is controlled using diuretics, and angiotensin converting enzyme (ACE) inhibitors. He underwent left ventriculography and...

  • Achieving medication titration for patients with heart failure in the real world. Hickey, A.; Suna, J.; Marquart, L.; Javorsky, G.; Munns, A.; Denaro, C.; Mudge, A.; Atherton, J. // Heart, Lung & Circulation;2015 Supplement 3, Vol. 24, pS193 

    No abstract available.

  • No benefit to early ACE inhibitor after CABG.  // Formulary;Oct2005, Vol. 40 Issue 10, p349 

    Reports that initiating therapy with ACE inhibitor quinapril within the first seven days after coronary artery bypass graft (CABG) surgery does not lead to better outcomes among patients already receiving optimal therapy. IMAGINE study led by Wiek H. van Gilst; Number of patients involved.

  • MERIT-HF – description of the trial. Wikstrand, J. // Basic Research in Cardiology;Nov2000 Supplement 1, Vol. 95, pI90 

    The MERIT-HF study was a randomized, double-blind, placebo-controlled trial with a single-blind, two-week placebo run-in period. There were two primary objectives: total mortality; and the combined endpoint of total mortality or all-cause hospitalizations (time to first event). Several other...

  • The background of the MERIT-HF trial. Dietz, R.; Osterziel, K.J.; Willenbrock, R.; Hänlein, D.; v.Harsdorf, R. // Basic Research in Cardiology;Nov2000 Supplement 1, Vol. 95, pI84 

    In the not so distant past, the idea of using beta-blockers as a primary therapy for congestive heart failure to improve symptoms and prognosis seemed paradoxical. The cardiac community reacted with skepticism when, in 1975, the pioneering report of Waagstein et al. appeared in the British Heart...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics